Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Argus Health
Johnson and Johnson
Farmers Insurance
US Army
Deloitte
AstraZeneca
Julphar
Queensland Health
Baxter

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 017962

« Back to Dashboard

NDA 017962 describes PARLODEL, which is a drug marketed by Us Pharms Holdings I and is included in one NDA. It is available from two suppliers. Additional details are available on the PARLODEL profile page.

The generic ingredient in PARLODEL is bromocriptine mesylate. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.
Summary for 017962
Tradename:PARLODEL
Applicant:Us Pharms Holdings I
Ingredient:bromocriptine mesylate
Patents:0
Therapeutic Class:Antiparkinson Agents
Hormonal Agents, Suppressant (Pituitary)
Formulation / Manufacturing:see details
Pharmacology for NDA: 017962
Ingredient-typeErgolines
Medical Subject Heading (MeSH) Categories for 017962
Suppliers and Packaging for NDA: 017962
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962 NDA Validus Pharmaceuticals LLC 30698-201 30698-201-30 30 CAPSULE, GELATIN COATED in 1 BOTTLE (30698-201-30)
PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962 NDA Validus Pharmaceuticals LLC 30698-201 30698-201-01 100 CAPSULE, GELATIN COATED in 1 BOTTLE (30698-201-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2.5MG BASE
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Mar 1, 1982TE:ABRLD:Yes

Expired US Patents for NDA 017962

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 ➤ Subscribe ➤ Subscribe
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Fuji
Boehringer Ingelheim
AstraZeneca
Deloitte
Cerilliant
Colorcon
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot